These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Clinical evaluation of cefmenoxime in internal medicine, with special reference to infections associated with hematological disorders].
    Author: Uchida T, Matsuda S, Kimura H, Satoh T, Ishibashi T, Kokubun K, Umezu H, Horikawa A, Saitoh T, Sakauchi Y.
    Journal: Jpn J Antibiot; 1984 Dec; 37(12):2506-18. PubMed ID: 6098743.
    Abstract:
    Clinical evaluation of cefmenoxime (CMX, Bestcall) was examined in the infection associated with hematological disorders, respiratory tract and other disorders. Clinical effectiveness for severe infection of hematological disorders was 47.4% in good and 84.2% in fair response, however, in the respiratory tract infections, 89.7% in good response was obtained. Opportunistic infection due to Gram-negative bacilli are often experienced in patients with hematological disorders. It was discussed that CMX would be a good therapeutic agent against infectious diseases associated with hematological disorders because it's antibacterial spectrum would be parallel to pathogens of such disorders.
    [Abstract] [Full Text] [Related] [New Search]